SCHEDULE 13G/A: Avoro Capital Advisors and Behzad Aghazadeh Maintain 8.9% Stake in Vera Therapeutics
Beneficial Ownership Report Amendment
Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have filed an amended Schedule 13G, reporting a continued beneficial ownership of 8.9% in Vera Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.
Summary
- Avoro Capital Advisors LLC and Behzad Aghazadeh collectively beneficially own 5,610,000 shares of Vera Therapeutics, Inc.'s Class A Common Stock.
- This ownership represents 8.9% of the total outstanding Class A Common Stock.
- The shares are held for investment purposes in the ordinary course of business and not with the intent to change or influence control of the issuer.
- The percentage of class is calculated based on 63,323,053 shares of Class A Common Stock outstanding as of November 5, 2024, as reported in Vera Therapeutics' Form 10-Q.
- Avoro Life Sciences Fund LLC is identified as having the right to receive dividends or proceeds from the sale of more than 5% of these shares.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is primarily informational, disclosing beneficial ownership. It is neutral in sentiment unless it signals a new activist stake or a significant divestment, neither of which is indicated here. This is an amendment, confirming an existing significant stake.
Future Outlook
NA
Industry Context
This filing is a standard disclosure required by the SEC when an entity acquires or updates beneficial ownership of more than 5% of a company's voting class of securities. It indicates a significant, continued investment by Avoro Capital Advisors, an investment adviser, in Vera Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such filings provide transparency regarding major shareholders and their investment intent, which is a routine aspect of investment management and corporate governance.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, potentially offering a signal of institutional confidence or interest.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarter for which Vera Therapeutics' Quarterly Report on Form 10-Q was filed. |
| 2024-11-05 | Date as of which 63,323,053 shares of Class A Common Stock were reported outstanding. |
| 2024-11-07 | Date Vera Therapeutics filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed by Avoro Capital Advisors LLC and Behzad Aghazadeh. |
Keywords
Vera Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Class A Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.